Abstract
Age-related macular degeneration (AMD) is a potentially blinding posterior segment disease; inflammatory responses and subretinal drusen formation lead to leaky blood vessels. The current treatment method involves intravitreal injections of anti-VEGF agents, which is highly invasive and requires frequent injections administered by trained personnel. Periocular injections such as trans-/intra-scleral injections would provide a minimally invasive treatment option. The sclera is the outermost protective layer occupying 5/6th of the ocular globe. Owing to its avascular nature and self-healing ability, sclera could be the potential space for the delivery of depot forming long-acting formulations. This project focuses on the development of chitosan grafted poly(n-isopropylacrylamide) (Cs-g-PNIPAAm) gel for the sustained intrascleral delivery of small molecular weight, multiple tyrosine kinase inhibitor Sunitinib malate.
Keywords
Ocular drug delivery, Microneedles, intrascleral
How to Cite
Gade, S., Larrañeta, E., Donnelly, R. F., Vanrell, R. H., Alvarez Lorenzo, C. I. & Thakur, R. S., (2022) “Development and characterization of injectable depot forming thermoresponsive hydrogel for the sustained intrascleral delivery of Sunitinib”, British Journal of Pharmacy 7(2). doi: https://doi.org/10.5920/bjpharm.1175
Funding
- Name
- H2020 Marie Skłodowska-Curie Actions
- Funding ID
- 813440
485
Views
107
Downloads
